TCGA-93-A4JO-01A-21R-A24X-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.370
- IL6_JAK_STAT3_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.260
- INTERFERON_ALPHA_RESPONSE+0.260
- INTERFERON_GAMMA_RESPONSE+0.260
- KRAS_SIGNALING_DN+0.180
- COMPLEMENT+0.100
- KRAS_SIGNALING_UP+0.090
- COAGULATION+0.070
- MYOGENESIS+0.060
Top 10 suppressed
- MYC_TARGETS_V1-0.580
- G2M_CHECKPOINT-0.570
- E2F_TARGETS-0.530
- MTORC1_SIGNALING-0.510
- OXIDATIVE_PHOSPHORYLATION-0.510
- PROTEIN_SECRETION-0.490
- MITOTIC_SPINDLE-0.400
- MYC_TARGETS_V2-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.390
- ANDROGEN_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.925 |
| 2 | TCGA-ZF-A9R7-01A-11R-A38B-07 | — | — | 0.912 |
| 3 | MNG882 | — | — | 0.907 |
| 4 | MNG450 | — | — | 0.907 |
| 5 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.904 |
| 6 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.904 |
| 7 | MDT-AP-2296 | Med | Medulloblastoma | 0.903 |
| 8 | TCGA-49-AAR4-01A-12R-A41B-07 | — | cohortA1 | 0.902 |
| 9 | TCGA-97-A4M7-01A-11R-A24X-07 | — | cohortA1 | 0.901 |
| 10 | 6b907244-c173-4e29-a163-24258a430477 | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |